全文获取类型
收费全文 | 9872篇 |
免费 | 751篇 |
国内免费 | 881篇 |
出版年
2024年 | 7篇 |
2023年 | 106篇 |
2022年 | 267篇 |
2021年 | 511篇 |
2020年 | 349篇 |
2019年 | 426篇 |
2018年 | 393篇 |
2017年 | 303篇 |
2016年 | 462篇 |
2015年 | 610篇 |
2014年 | 766篇 |
2013年 | 806篇 |
2012年 | 933篇 |
2011年 | 910篇 |
2010年 | 530篇 |
2009年 | 480篇 |
2008年 | 527篇 |
2007年 | 508篇 |
2006年 | 427篇 |
2005年 | 338篇 |
2004年 | 254篇 |
2003年 | 290篇 |
2002年 | 205篇 |
2001年 | 165篇 |
2000年 | 146篇 |
1999年 | 151篇 |
1998年 | 91篇 |
1997年 | 73篇 |
1996年 | 90篇 |
1995年 | 66篇 |
1994年 | 44篇 |
1993年 | 33篇 |
1992年 | 54篇 |
1991年 | 40篇 |
1990年 | 26篇 |
1989年 | 33篇 |
1988年 | 13篇 |
1987年 | 19篇 |
1986年 | 13篇 |
1985年 | 14篇 |
1984年 | 9篇 |
1983年 | 11篇 |
1982年 | 3篇 |
1981年 | 1篇 |
1980年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
981.
982.
Tang TT Zhu ZF Wang J Zhang WC Tu X Xiao H Du XL Xia JH Dong NG Su W Xia N Yan XX Nie SF Liu J Zhou SF Yao R Xie JJ Jevallee H Wang X Liao MY Shi GP Fu M Liao YH Cheng X 《PloS one》2011,6(9):e24272
Objective
Animal studies suggest that regulatory T (Treg) cells play a beneficial role in ventricular remodeling and our previous data have demonstrated defects of Treg cells in patients with chronic heart failure (CHF). However, the mechanisms behind Treg-cell defects remained unknown. We here sought to elucidate the mechanism of Treg-cell defects in CHF patients.Methods and Results
We performed flow cytometry analysis and demonstrated reduced numbers of peripheral blood CD4+CD25+FOXP3+CD45RO−CD45RA+ naïve Treg (nTreg) cells and CD4+CD25+FOXP3+CD45RO+CD45RA− memory Treg (mTreg) cells in CHF patients as compared with non-CHF controls. Moreover, the nTreg/mTreg ratio (p<0.01), CD4+CD25+FOXP3+CD45RO− CD45RA+CD31+ recent thymic emigrant Treg cell (RTE-Treg) frequency (p<0.01), and T-cell receptor excision circle levels in Treg cells (p<0.01) were lower in CHF patients than in non-CHF controls. Combined annexin-V and 7-AAD staining showed that peripheral Treg cells from CHF patients exhibited increased spontaneous apoptosis and were more prone to interleukin (IL)-2 deprivation- and CD95 ligand-mediated apoptosis than those from non-CHF individuals. Furthermore, analyses by both flow cytometry and real-time polymerase chain reaction showed that Treg-cell frequency in the mediastinal lymph nodes or Foxp3 expression in hearts of CHF patients was no higher than that of the non-CHF controls.Conclusion
Our data suggested that the Treg-cell defects of CHF patients were likely caused by decreased thymic output of nascent Treg cells and increased susceptibility to apoptosis in the periphery. 相似文献983.
984.
Guan R Purohit S Wang H Bode B Reed JC Steed RD Anderson SW Steed L Hopkins D Xia C She JX 《PloS one》2011,6(4):e17822
Background
Chemokine (C-C motif) ligand 2 (CCL2), commonly known as monocyte chemoattractant protein-1 (MCP-1), has been implicated in the pathogenesis of many diseases characterized by monocytic infiltration. However, limited data have been reported on MCP-1 in type 1 diabetes (T1D) and the findings are inconclusive and inconsistent.Methods
In this study, MCP-1 was measured in the sera from 2,472 T1D patients and 2,654 healthy controls using a Luminex assay. The rs1024611 SNP in the promoter region of MCP-1 was genotyped for a subset of subjects (1764 T1D patients and 1323 controls) using the TaqMan-assay.Results
Subject age, sex or genotypes of MCP-1 rs1024611SNP did not have a major impact on serum MCP-1 levels in either healthy controls or patients. While hemoglobin A1c levels did not have a major influence on serum MCP-1 levels, the mean serum MCP-1 levels are significantly higher in patients with multiple complications (mean = 242 ng/ml) compared to patients without any complications (mean = 201 ng/ml) (p = 3.5×10−6). Furthermore, mean serum MCP-1 is higher in controls (mean = 261 ng/ml) than T1D patients (mean = 208 ng/ml) (p<10−23). More importantly, the frequency of subjects with extremely high levels (>99th percentile of patients or 955 ng/ml) of serum MCP-1 is significantly lower in the T1D group compared to the control group (odds ratio = 0.11, p<10−33).Conclusion
MCP-1 may have a dual role in T1D and its complications. While very high levels of serum MCP-1 may be protective against the development of T1D, complications are associated with higher serum MCP-1 levels within the T1D group. 相似文献985.
986.
Sohn CS Cheng TT Drummond ML Peng ED Vermont SJ Xia D Cheng SJ Wastling JM Bradley PJ 《PloS one》2011,6(4):e18383
Neospora caninum is an important veterinary pathogen that causes abortion in cattle and neuromuscular disease in dogs. Neospora has also generated substantial interest because it is an extremely close relative of the human pathogen Toxoplasma gondii, yet does not appear to infect humans. While for Toxoplasma there are a wide array of molecular tools and reagents available for experimental investigation, relatively few reagents exist for Neospora. To investigate the unique biological features of this parasite and exploit the recent sequencing of its genome, we have used an organelle isolation and monoclonal antibody approach to identify novel organellar proteins and develop a wide array of probes for subcellular localization. We raised a panel of forty-six monoclonal antibodies that detect proteins from the rhoptries, micronemes, dense granules, inner membrane complex, apicoplast, mitochondrion and parasite surface. A subset of the proteins was identified by immunoprecipitation and mass spectrometry and reveal that we have identified and localized many of the key proteins involved in invasion and host interaction in Neospora. In addition, we identified novel secretory proteins not previously studied in any apicomplexan parasite. Thus, this organellar monoclonal antibody approach not only greatly enhances the tools available for Neospora cell biology, but also identifies novel components of the unique biological characteristics of this important veterinary pathogen. 相似文献
987.
Clare F. Price David Tyssen Secondo Sonza Ashley Davie Sonya Evans Gareth R. Lewis Shirley Xia Tim Spelman Peter Hodsman Thomas R. Moench Andrew Humberstone Jeremy R.A. Paull Gilda Tachedjian 《PloS one》2011,6(9)
SPL7013 Gel (VivaGel®) is a microbicide in development for prevention of HIV and HSV. This clinical study assessed retention and duration of antiviral activity following vaginal administration of 3% SPL7013 Gel in healthy women. Participants received 5 single doses of product with ≥5 days between doses. A cervicovaginal fluid (CVF) sample was collected using a SoftCup™ pre-dose, and immediately, or 1, 3, 12 or 24 h post-dose. HIV-1 and HSV-2 antiviral activities of CVF samples were determined in cell culture assays. Antiviral activity in the presence of seminal plasma was also tested. Mass and concentration of SPL7013 in CVF samples was determined. Safety was assessed by reporting of adverse events. Statistical analysis was performed using the Wilcoxon signed-rank test with Bonferroni adjustment; p≤0.003 was significant. Eleven participants completed the study. Inhibition of HIV-1 and HSV-2 by pre-dose CVF samples was negligible. CVF samples obtained immediately after dosing almost completely inhibited (median, interquartile range) HIV-1 [96% (95,97)] and HSV-2 [86% (85,94)], and activity was maintained in all women at 3 h (HIV-1 [96% (95,98), p = 0.9]; HSV-2 [94% (91,97), p = 0.005]). At 24 h, >90% of initial HIV-1 and HSV-2 inhibition was maintained in 6/11 women. SPL7013 was recovered in CVF samples obtained at baseline (46% of 105 mg dose). At 3 and 24 h, 22 mg and 4 mg SPL7013, respectively, were recovered. More than 70% inhibition of HIV-1 and HSV-2 was observed if there was >0.5 mg SPL7013 in CVF samples. High levels of antiviral activity were retained in the presence of seminal plasma. VivaGel was well tolerated with no signs or symptoms of vaginal, vulvar or cervical irritation reported. Potent antiviral activity was observed against HIV-1 and HSV-2 immediately following vaginal administration of VivaGel, with activity maintained for at least 3 h post-dose. The data provide evidence of antiviral activity in a clinical setting, and suggest VivaGel could be administered up to 3 h before coitus.
Trial Registration
The study is registered at ClinicalTrials.gov under identifier: NCT00740584相似文献988.
989.
Aurora A is an important oncogenic kinase for mitotic spindle assembly and a potentially attractive target for human cancers. Its activation could be regulated by ATP cycle and its activator TPX2. To understand the activation mechanism of Aurora A, a series of 20 ns molecular dynamics (MD) simulations were performed on both the wild-type kinase and its mutants. Analyzing the three dynamic trajectories (Aurora A-ATP, Aurora A-ADP, and Aurora A-ADP-TPX2) at the residue level, for the first time we find two TPX2-dependent switches, i.e., switch-1 (Lys-143) and switch-2 (Arg-180), which are tightly associated with Aurora A activation. In the absence of TPX2, Lys-143 exhibits a "closed" state, and becomes hydrogen-bonded to ADP. Once TPX2 binding occurs, switch-1 is forced to "open" the binding site, thus pulling ADP away from Aurora A. Without facilitation of TPX2, switch-2 exits in an "open" conformation which accompanies the outward-flipping movement of P·Thr288 (in an inactive conformation), leading to the crucial phosphothreonine exposed and accessible for deactivation. However, with the binding of TPX2, switch-2 is forced to undergo a "closed" movement, thus capturing P·Thr288 into a buried position and locking its active conformation. Analysis of two Aurora A (K143A and R180A) mutants for the two switches further verifies their functionality and reliability in controlling Aurora activity. Our systems therefore suggest two switches determining Aurora A activation, which are important for the development of aurora kinase inhibitors. 相似文献
990.
目的:观察瑞舒伐他汀对新西兰大白兔心肌梗死后左室重构及心肌细胞凋亡的影响。方法:45只雄性新西兰大白兔随机分成三组,即:假手术组(S,n=15),心肌梗死对照组(MI,n=15),心肌梗死瑞舒伐他汀干预组(R,n=15)MI组和R组大鼠结扎左冠状动脉前降支建立AMI模型。心肌梗死对照组及假手术组术后24h灌等量的生理盐水。瑞舒伐他汀干预组于术后24h直接灌胃法给药,给药剂量以10mg/kg*d计算。干预2周后,进行心脏超声测定,随即处死新西兰大白兔、取出心脏,观察病理组织形态,并通过Western blot方法检测Bcl-2,Bax在心肌梗死边缘区的蛋白表达。结果:①心脏超声检测表明干预组左室舒张末内径(LVEDD)、左室收缩末内径(LVESD)较心肌梗死对照组降低而左室射血分数(LVEF)较心肌梗死对照组增高②干预组心肌梗死边缘区Bax表达与心肌梗死对照组比较未见统计学差异,而Bcl-2表达高于心肌梗死对照组。结论:瑞舒伐他汀上调Bcl-2的表达,改善心室重构 相似文献